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awaiting for inclusion in the genus. Furobacterium nucleaturn has 5 sub- 
species and Ewrium includes E p s e u d o n e m p h m .  The bile-sensitive 
former Bgrm'lis now are Campylobacter gradis; the bile-resistance 
ones belong to a new genus Sutterelle as S.wadnuorthiensis. 
Identification of gram-negative anaerobes beyond group level as 
obtained by rapid testing is rarely indicated, unless the case is un- 
usual, complicated and the culture result is likely to affect the ther- 
apy. Accurate species identification traditionally requires a battery of 
biochemical tests and metabolic end product or cellular fatty acid 
analysis by GLC. A rapid, less expensive but yet potential approach 
is the detection of performed enzymes. Heavy inoculum and short 
(4 h) incubation in air minimizes contamination and provides rapid 
results. Tablet or spot enzyme subtrates allow tailoring of identifi- 
cation sets at low cost. For accurate identification of anaerobes and 
for taxonomic purposes, reference laboratories find cellular fatty acid 
profiling, 16s rRNA sequencing and DNA probes valuable. 
Sacternides fragiis Polysaccharides Mediate 
lntraabdominal Abscess Formation 
D.L. Kasper, A.O. Tzianabos. Channing hboratory, Brigham and 
Women? Hospital, Harvard Medical School, Boston, MA, USA 
Bacteroides hgilis is one of the bacterial species which has the 
propensity to induce abscesses which are one of the characteristic 
host pathological responses to infection. The B. J?agilis component 
responsible for abscess induction is a unique capsular polysaccharide 
complex comprising two hstinct polysaccharides, PS A and PS B. 
In animal models, PS A is more potent than PS B in inducing ab- 
scesses when implanted directly into the peritoneum. Each repeating 
unit of PS A has one positively charged group (a h e  amino residue) 
and one negatively charged group (pyruvate). Chemical techniques 
were used to neutrahe the charge on either of these residues and 
resulted in polysaccharides that were not able to induce abscesses. 
Another unique biologic attribute of PS A is its abihty to prevent 
the development of inmaabdominal abscesses caused by B. jagilis and 
by other unrelated bacteria capable of inducing abscesses. Kinetic 
studies demonstrated that PS A was protective against abscesses even 
when given 4 hours after intraperitoneal bacterial challenge. Im- 
munologic studies indicated that CD4+ T cells were able to transfer 
to naive rats protection against abscesses. In vitro studies demon- 
strated potent mitogenic stimulation by PS A on nonimmune CD4+ 
T cells in the presence of feeder cells. Charge neutralization of PS A 
eliminates its mitogenic capacity. PS A has many biological propemes 
that are unusual for polysaccharides that are related to the distinctive 
structural attributes of t h i s  molecule. 
Anaerobic Bacteria in Respiratory Tract 
Infections 
C.E. Nord. Huddinge Uniwrsity Hospital, kizrolinska Institute, 
Stockholm, Sweden 
The anaerobic bacteria which predominate in respiratory tract infec- 
tions are Bacferoides Jagilis group, Prevotella, Porphyromonas, Fusobac- 
terium and Peptosfreptococrur species. These bacteria have one or more 
virulence factors including the adhesion to epithelial surfaces, the 
invasion of cell tissues, the production of toxins/enzymes and the 
cell surfaces constituents. Most anaerobic bacteria involved in res- 
piratory tract infections were susceptible to the antimicrobial agents 
used until a few years ago. Resistance to different agents such as 
beta-kctam antibiotics, clindamycin and memnidazole has been de- 
scribed during the last years. Resistance is of major importance in 
the B. jagilis group. While other groups of anaerobic bacteria have 
remained substantally stable in their susceptibility patterns, the Bac- 
teroides group and Prevotella, Porphyromonas and Fusobactm'um species 
have become increasingly resistant to many anti-anaerobic agents as 
their use have become more widespread. Antimicrobial therapy of 
anaerobic infections must be prolonged to avoid relapses, because of 
the marked tendency for anaerobes to cause tissue necrosis, abscess 
formation and septic thrombophlebitis. Drugs commonly used in the 
treatment of anaerobic respiratory tract infections are beta-lactam an- 
tibiotics, clindamycin, metronidamle and beta-lactam compounds in 
combination with beta-lactamase inhibitors. 
F] Anaerobic Bacteria in lntraabdominal Infections 
H. Giamarellou. Athens University School OfMediCine, Athens, Greece 
The majority of IAI are secondary to contamination of the peri- 
toneal cavity with enteric organisms after injury to the gastroin- 
testinal tract or as sequelae of pathologic processes leading to organ 
ischemia. Therefore MI are endogenous derived from the microbial 
flora of the gastrointestinal tract which is the most complex microbial 
ecosystem of the manunah ' body with up to lo'* viable bacteria 
per gram of gut content, and up to 400-500 different species. Newly 
described species like Bilofila wadsworba, is implicated in -50% 
of patients with gangrenous and perforated appendicitis. B. f m g h  
however still represents the most commonly encountered species. Its 
specific virulence factors providing an explation for its unique im- 
plication in IAI include: (I) The capsule that protects against phago- 
cytosis, 01) the fimbriae that attach directly to peritoneal mesothelial 
cells, (III) the production of heparinase and chondroitin sulfatase. 
The most important factor in the treatment of inmaabdominal infec- 
tions are early diagnosis and prompt surgical intervention while an- 
tibiotic play a secondary role. Antianaerobic agents include chloram- 
phenicol, dindamycin and the nimimidazoles while the inhibitors, 
cefoxitin, cefotetan, ceftizoxime, carbapenems and some advanced 
quinolones like mvafloxacin represent single drugs to cover both 
aerobic gram negatives and anaerobic microflora. Although that al- 
most all climcal trials usually end up with >900/0 efficacy rate, the 
final outcome is dependant on the stage of the mfection (early versus 
late), sepsis score, underlying diseases and the applied surgical proce- 
dures. The choice of antibiotic@) must be influenced by its toxicity, 
local nosocomial susceptibility patterns, resistance inducing abihty 
and the cost. 
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I S150 I G-CSF, an Anti-inflammatory Cytokine: Its 
Potential Role in Infectious Disease 
T. Hartung, H.-D. Volk, A. Wendel. Uniuersify OfKonstanz, Germany 
In three double-blind placebo conmlled studies, a total of 56 healthy 
volunteers were treated S.C. with G-CSF (NeupogenR). G-CSF 
treatment raised blood neutrophil (PMN) counts lOfold and primed 
PMN functions such as oxidative burst, bactericidal killing as well 
as release of interleukin-1 receptor antagonist and soluble TNF re- 
ceptors. However, degranulation was d e c t e d  and the release of 
the chemokme leukomene B4 was even attenuated. Thus, G-CSF is 
not a mere PMN activator but Meentially regulates Merent PMN 
functions. 
In addition, single injection of G-CSF resulted also in a a-ansient 
2-3 fold monocytosis. When whole blood of G-CSF treated donors 
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was stimulated by bacterial endotoxin (LPS), monocyte release of 
TNFa and IL-12 was attenuated while prostaglandin E2 release was 
increased. Thus, G-CSF treatment resulted in an anti-inflammatory 
mediator pattern ex vivo. 
Furthermore, ex vivo LPS-inducible release of interferon-yby 
lymphocytes was attenuated. Moreover, sustained daily G-CSF treat- 
ment resulted in lymphocytosis maximal at day 8 of treatment. 
Taking together these pleitropic effects of G-CSF, this cytokine 
appears to be rather a mere hematopoetic growth factor but 
a general biological response modher with anti-bactericidal and 
anti-dammatory characteristics. These findmgs might explain the 
relatively few adverse events of GCSF reported in more than 1.4 
million treated patients. In conclusion, these findings prompt c h -  
ical trials in septic shock prophyhs, HIV infection and chronic 
inflammation. 
I S151 I HIV Disease-Related Neutropenia: An 
Independent Risk Factor for Severe Infections 
P. Hermans, B. Sommereijns, N. Clumeck. Centre Hospitalier 
Universitaire St-Pierre, Bmsels, Belgium 
To assess the risk mfections associated with neutropenia (N) in 
HIV-infected patients, we reviewed clinical, immunological and 
hematological data of 1870 encoded patients’ files, h m  which 1403 
were considered as evaluable for descriptive analyses. From those pa- 
tients, 177 neutropenic patients were compared with 177 controls 
matched for cd4+ cells at the time of neutropenia and time of first 
visit in the department. Descriptive analyses and development of 
logistic models were used to determine factors associated with the 
further risk of development of bacterial mfections (bacteriemia and 
pneumonia) or major fungal infections. 
Results: The occurrence of severe bacterial and fungal infections 
was sigufkntly associated with neutropenia (p = 0.0001) in the 
case-control analysis. Bacteriemia was more common in neutropenic 
patients than in non-neutropenic patients (p = 0.016). The risk of 
N-induced infections was also strongly associated with the dim- 
cal stage (AIDS) and hemoglobin level (p = 0.00001). Neutropenic 
episodes occured preferendally in the recent period of observation 
(1991-1993), likely due to prolonged survival and the increasing use 
of myelosuppressive therapies for treating both HIV and opportunis- 
tic infections. 
Conclusions: 1) HIV-1 infected Patients with neutropenia are 
sigtllficantly at risk of developing severe bacterial or fungal infec- 
tions. 2) This increased risk of secondary N-associated infections 
occurs at the end stage of HIV disease and growth factors could 
dramatically impme the quality of life of advanced HIV patients 
with haematological abnormalities. A prospective case-control study 
confirmed that filgrastim-treated neutropenic patients had fewer bac- 
terial infections and related hospital days (xuritzkes D et al, 1997). 
Recently, we also showed that Protease inhibitors were effective tools 
in restoring cytopenia, mainly neutropenia and thrombopenia, in a 
substantial number of advanced HIV individuals (1997) 
Prevention of Bacterial Infection in Advanced 
HIV Patients: Results of a Prospective 
Randomized Controlled Trial 
R. Mitsuyasu. University .f California, Los Angeles, USA 
Several previous studies of G-CSF in patients (pts) with HIV in- 
fection have demonstrated that filgrastim (r-met-HUG-CSF) can 
mcrease neutrophil counts, improve neutrophil function and re- 
verse severe neutropenia in patients with HIV infection. The ef- 
fects of filgrastim to prevent severe neutropenia (ANC < 500/mm3) 
was stuhed in 250 moderately neutropenic (ANC 75C-1000/mm3) 
HIV-infected individuals with CD4 < 200/mm3. Pts were ran- 
domized to receive fdgzastim (n = 172) either 1.0 mcg/kg/day 
or 300 mcg 2-5 times/wk SC titrated to maintain ANC between 
2000-10,000/mm3 or to an observational control group (n = 86). 
If ANC < 500/mm3, two consecutive times, control patients could 
crossover to fdgrastim. Baseline characteristics were well-balanced 
between the groups. Intent-to-treat analyses of clinical endpoints, 
both adjusted and unadjusted, were performed. Incidence of severe 
neutropenia was sigmficantly lower during the 24 wk study pe- 
riod in the filgrastim groups (1.7%) vs control (22%), (p < 0.001). 
Incidence of overall bacterial infection was 31% lower in the filgras- 
tim-treated group (2.93 vs 4.25/1000 pt days, p 0.03 adjusted). Fil- 
grastim-treated pts also had 54% fewer severe bacterial infections @ 
= 0.01 adjusted). Filgrastim-treated pts had 45% fewer hospital days 
for bacterial infections and used less IV antibiotics. No difference 
in incidence of fungal infection could be observed. No unexpected 
or new adverse events were observed. There were no Werences 
in plasma HIV-1 RNA leveIs between groups. Filgrastim therapy is 
safe and effective in preventing severe neutropenia and in reducing 
incidence of bacterial mfection in HIV-infected individuals. 
I S153 I Filgrastim (r-metHuG-CSF) Treatment of 
HIV-Infected Patients Improves Neutrophil 
Function 
D. Pitrak’, K. Mullane’, M. Bilek’, A. Skariah ’, L. Porter’, 
R. Wong ’, H. Namini ’, R.C. Allen ’, €? Stevens ’. ’ University .f 
Illinois, Chicago, IL, USA, ’Amgen Inc., Thousand Oak, CA, USA, 
3ExOxEmis Inc., San Antonio, TX, USA 
Objectives: To determine the effect of Filgrastim treatment on neu- 
trophil (PMNL) function in HIV-infected patients. 
Methods: We treated seventy-six HIV-infected patients at dif- 
ferent stages of disease with Filgrastim 300 kg sc qd or qod for 8 
days. Twenty-eight normal volunteers served as controls. We mea- 
sured PMNL oxidative metabolism by chemiluminescence (CL) of 
oxygenated luminigenic substrates in whole blood after simulation 
with human complement opsonized zymosan (hC-OPZ) and killing 
of E. coli at a bacteria to PMNL ratio of 1:l.  
Results: Bacterial killing was impaired for patients with late stage 
HIV infection (CD4+ < 200/mm3). CL (counts/PMNL./20 mir- 
Utes) in response to hC-OPZ after priming with human PAF (Max- 
imal Opsonin Receptor Expression, MORE) was also decreased for 
late stage patients. Patients at all stages of disease before treatment 
showed an increase in unprimed CL to hC-OPZ (Circulating Op- 
sonin Receptor Expression, CORE) relative to MORE. T h  in- 
creased CORE/MORE ratio indicates in vivo activation. Treatment 
with Filgrastim caused a sgnhcant increase in CL and bacterial 
ldhng, and sigdcant decreases in the COREIMORE ratio. Data 
shown for daily dosing. 
Conclusions: Filgrastim treatment in HIV-infected patients in- 
creases PMNL oxidative metabolism, corrects dysfunction in PMNL 
oxidative metabolism and bacterial killing in late stage patients, and 
reduces in vivo activation of circulating PMNL. Therapy with Fil- 
grastim in HIV infection not only increases PMNL numbers, but also 
improves function and is of potential benefit in preventing and/or 
treating secondary dections complications. 
